Untitled Page

   Clinical Research Support | Departments | Trials | Frequently Asked Questions | Request Trial Information

 

Clinical Trial Listing

001: FOR MORE INFORMATION ON ANY OF THESE TRIALS PLEASE CALL 504-842-4481 
Call 504-842-4481 to reach the main line for the Ochsner Cancer Institute Clinical Trials Department. Leave a message with a summary of your diagnosis and/or trial interests and we will call you back as soon as possible
 
2010.011.N - Prostate Cancer and the effects of Radiation Therapy with or without Androgen-Deprivation Therapy 
This randomized phase III trial is studying radiation therapy to see how well it works compared with radiation therapy given together with androgen-deprivation therapy in treating patients with prostate cancer.
 
2010.208.N - Prostate Cancer (with a Rising PSA After Radical Prostatectomy) and the effects of Short-Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed-Only Radiotherapy (SPPORT) 

This randomized phase III trial is studying prostate radiation therapy to see how well it works compared with short-term androgen deprivation therapy given together with pelvic lymph node radiation therapy with or without prostate radiation therapy in treating patients with a rising PSA after surgery for prostate cancer.

 


 
2012.160.A - Chemo-Inducted Nausea and Vomiting and the Effects of IV Fosaprepitant Dimeglumine 

This study aims to demonstrate that, when given concomitantly with a 5-hydroxytryptamine 3 (5-HT3) antagonist and a corticosteroid, a single 150 mg intravenous (IV) dose of fosaprepitant given on Day 1 is superior to the control regimen of 5-HT3 and corticosteroid only, in preventing chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC).

 
2013.146.B - Carcinoid Tumors and the Effects of Pazopanib vs. Placebo 

This randomized phase II trial studies how well pazopanib hydrochloride works in treating patients with progressive carcinoid tumors. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.


 
2013.162.N - Prostate Cancer and the Effects of Androgen-Deprivation Therapy and Radiation Therapy 

Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells. This randomized phase III trial studies androgen-deprivation therapy and radiation therapy in treating patients with prostate cancer.


 
2013.165.N - High-Risk Prostate Cancer and the Effects of Hormone Therapy, Radiation Therapy, and TAK-700 

Androgens can cause the growth of prostate cancer cells. Drugs, such as steroid 17alpha-monooxygenase TAK-700, when used with other hormone therapy, may lessen the amount of androgens made by the body. Radiation therapy uses high energy x rays to kill tumor cells. This may be an effective treatment for prostate cancer when combined with hormone therapy. Studying quality-of-life in patients having cancer treatment may help identify the intermediate- and long-term effects of treatment on patients with prostate cancer.  This randomized phase III trial is studying the use of hormone therapy, including TAK-700, together with radiation therapy in treating patients with prostate cancer.


 

Search by Keyword

Request Trial Information

NIH Logo

Ochsner Specialty Research Locations

Browse by Subject

Browse by Location

menu top
Left Menu Home Small
Left Menu CTU Small
Left Menu Leadership Small
Left Menu Give Small
Left Menu Contact Small
Left Menu UQ
menu bottom
Untitled Page